Karyopharm Therapeutics plans up to $50 million at-the-market offering

Deal raises funds for clinical trials; Cantor Fitzgerald assists

By Marisa Wong

Morgantown, W.Va., May 19 – Karyopharm Therapeutics Inc. plans to raise up to $50 million through an at-the-market offering of common stock, according to a 424B5 filing with the Securities and Exchange Commission.

Cantor Fitzgerald & Co. will act as underwriter.

Proceeds will be used to support ongoing clinical developments, for clinical trials, to build the company’s commercial infrastructure and for working capital and other general corporate purposes.

The company’s stock closed at $8.18 per share (Nasdaq: KPTI) on May 18.

Karyopharm is a clinical-stage pharmaceutical company focused on drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. The company is based in Newton, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.